# FeDeriCa (NCT03493854)

> A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03493854
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Early Breast Cancer
- Interventions: Cyclophosphamide; Doxorubicin; Docetaxel; Paclitaxel; Pertuzumab IV; FDC of Pertuzumab and Trastuzumab SC; Trastuzumab IV; Trastuzumab SC; Surgery; Post-operative Radiotherapy; Hormone Therapy
- Enrollment: 500
- Primary outcome: Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8)

## Commentary we found

- YouTube: 6
- Podcasts: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=federica-nct03493854

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03493854", "email": "<work email>"}; the inbox owner confirms by the emailed link.